Abstract
In oncology clinical trials, elderly are often under-represented and this status quo still persists despite a clear need for efficacy data in this age category.1 This is due to several...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
